ES2052475T1 - Preparacion farmaceutica para el tratamiento de trastornos inmunoorganicos comprendiendo pp14 o anticuerpos pp14. - Google Patents

Preparacion farmaceutica para el tratamiento de trastornos inmunoorganicos comprendiendo pp14 o anticuerpos pp14.

Info

Publication number
ES2052475T1
ES2052475T1 ES92305970T ES92305970T ES2052475T1 ES 2052475 T1 ES2052475 T1 ES 2052475T1 ES 92305970 T ES92305970 T ES 92305970T ES 92305970 T ES92305970 T ES 92305970T ES 2052475 T1 ES2052475 T1 ES 2052475T1
Authority
ES
Spain
Prior art keywords
immunoorganic
antibodies
treatment
pharmaceutical preparation
disorders including
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES92305970T
Other languages
English (en)
Inventor
Alan Suite Drizen
Anthony E Bolton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intermune Life Sciences Inc
Original Assignee
Intermune Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/720,591 external-priority patent/US5256411A/en
Application filed by Intermune Life Sciences Inc filed Critical Intermune Life Sciences Inc
Publication of ES2052475T1 publication Critical patent/ES2052475T1/es
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE PRESENTA UN METODO PARA TRATAR UNA ENFERMEDAD EN EL SISTEMA INMUNE EN LOS HUMANOS MEDIANTE LA ADMINISTRACION DE UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE UNA SUSTANCIA ACTIVA SELECCIONADA ENTRE EL GRUPO QUE CONSTA DE PP14, DERIVADOS DEL PP14, MUTEINAS DEL PP14, FRAGMENTOS DEL PP14, Y SUBUNIDADES DEL PP14, PARA ALIVIAR LA ENFERMEDAD DEL SISTEMA INMUNE.
ES92305970T 1991-06-28 1992-06-29 Preparacion farmaceutica para el tratamiento de trastornos inmunoorganicos comprendiendo pp14 o anticuerpos pp14. Pending ES2052475T1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/720,591 US5256411A (en) 1989-01-11 1991-06-28 Immune cell proliferation inhibitors

Publications (1)

Publication Number Publication Date
ES2052475T1 true ES2052475T1 (es) 1994-07-16

Family

ID=24894577

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92305970T Pending ES2052475T1 (es) 1991-06-28 1992-06-29 Preparacion farmaceutica para el tratamiento de trastornos inmunoorganicos comprendiendo pp14 o anticuerpos pp14.

Country Status (6)

Country Link
EP (1) EP0520834A3 (es)
JP (1) JPH05201874A (es)
AU (1) AU646165B2 (es)
CA (1) CA2064544A1 (es)
DE (1) DE520834T1 (es)
ES (1) ES2052475T1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107469A0 (en) * 1992-11-03 1994-02-27 Intermune Life Sciences Inc Pharmaceutical compositions for preventing miscarriage and infertility
IL111743A0 (en) * 1993-12-08 1995-01-24 Intermune Life Sciences Inc Recombinant genes expressing pp14
EP2403875A1 (en) 2009-03-06 2012-01-11 Tripath Imaging, Inc. Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer
WO2013177102A2 (en) * 2012-05-21 2013-11-28 Felder Mitchell S Treatment of cancer by manipulating the immune system

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039521A (en) * 1989-01-11 1991-08-13 Hyal Pharmaceutical Corporation Immune cell proliferation inhibitors

Also Published As

Publication number Publication date
EP0520834A3 (en) 1993-06-09
JPH05201874A (ja) 1993-08-10
EP0520834A2 (en) 1992-12-30
DE520834T1 (de) 1994-05-26
CA2064544A1 (en) 1992-12-29
AU646165B2 (en) 1994-02-10
AU1806892A (en) 1992-08-13

Similar Documents

Publication Publication Date Title
ES2061799T3 (es) Nuevo preparado medicamentoso y procedimiento para su preparacion.
IT1220979B (it) Capsule contenenti un allergene e procedimento per la loro preparazione
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
BR0115392A (pt) Método para o tratamento de uma doença sensìvel a interferona em um animal de sangue quente, método para individualizar as dosagens de uma interferona no tratamento, método para a fabricação de um dispositivo de liberação de efeito terapêutico de longa duração de uma droga ao longo de um perìodo de tempo, e conjunto útil para a ministração de uma quantidade relativamente constante de uma droga
MX9301348A (es) Nuevos compuestos que tienen actividad farmacologica, proceso para su preparacion y composicion farmaceutica que los comprende.
ATE209908T1 (de) RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
BR9106114A (pt) Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica
NO177376C (no) Fremgangsmåte for fremstilling av en farmasöytisk doseringsform basert på en tampongtrykkmetode
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
RU94045825A (ru) Применение материала, полученного из mycobacterium vaccae для производства терапевтического средства для лечения психических заболеваний, способ лечения психических заболеваний, продукт, содержащий антигенный и/или иммунорегуляторный материал, фармацевтическое средство
DK0412554T3 (da) Sustained-release-præparat til administration i hjernen
PT97300A (pt) Processo para a preparacao de esteres de acidos 1,4-di-hidropiridinocarboxilicos n-alquilados e de medicamentos que os contem
ES2059312T3 (es) Medicamento que puede administrarse por via nasal, procedimiento para su preparacion y su aplicacion.
ES2052475T1 (es) Preparacion farmaceutica para el tratamiento de trastornos inmunoorganicos comprendiendo pp14 o anticuerpos pp14.
MX9303023A (es) Composicion farmaceutica para tratar desordenes gastricos.
DK0521057T3 (da) Farmaceutiske midler indeholdende ipriflavon, fremgangsmåde til fremstilling deraf, og relativ terapeutisk anvendelse
NO810480L (no) Anologifremgangsmaate for fremstilling av terapeutisk aktive 1,3,4-oksadiazolylfenol-derivater
ES2076274T3 (es) Sustancia cpc farmacologicamente activa, proceso para su preparacion y su utilizacion en la terapia.
DE3380923D1 (de) Pharmazeutische zusammensetzungen zur behandlung von stoerungen, bedingt durch humanendrogen.
ATE5073T1 (de) 5-amino-tetrazol-derivate von retinsaeuren, ihre herstellung und diese enthaltende pharmazeutische zubereitungen.
DE3879837D1 (de) Pharmazeutische praeparate zur behandlung von zereberalen psycho-organischen syndromen.
SE8105500L (sv) Psykotropa lekemedel
TH55145A3 (th) วิธีการสำหรับป้องกันการเริ่มมีอาการเป็นโรคหืด
RU94037731A (ru) Способ лечения рассеянного склероза
TH13515A (th) สารที่ใช้เป็นยาสำหรับรักษาอาการอักเสบหรือบรรเทาอาการปวด